In a major public health outreach effort, health authorities in France are mailing personalized letters to 1.6 million women using desogestrel-only contraceptives, such as Antigone and Cerazette, to inform them of a statistically low but elevated risk of developing a meningioma after prolonged use.
In Plain English: The Clinical Takeaway
- The Medication: Desogestrel is a progestin-only pill (commonly dosed at 75 micrograms) used to prevent pregnancy. Brand names include Antigone, Cerazette, Elfasette, and Optimizette.
- The Risk: Long-term use—particularly exceeding five to seven years—is associated with a small, measurable increase in the risk of developing a meningioma, a mostly non-cancerous tumor of the protective membranes surrounding the brain.
Understanding the Epidemiological Data and the Epi-Phare Study
The regulatory notification stems from epidemiological data, notably a 2024 study conducted by Epi-Phare, a scientific interest group. According to the findings, the absolute risk remains low: approximately one in every 67,000 women who have taken desogestrel develops a related meningioma. However, that probability rises to one in 17,000 for women undergoing five or more years of treatment.
Further analysis shows that the relative risk is multiplied by two after seven years of use. Crucially, the epidemiological data demonstrates that this elevated risk recedes, disappearing one year after discontinuing the progestin. The hazard is most pronounced among women over the age of 45 and those who have previously used a progestin medication considered as high-risk for more than one year.
| Exposure Duration / Cohort | Estimated Incidence | Clinical Context |
|---|---|---|
| General Desogestrel User Cohort | 1 in 67,000 women | Baseline risk associated with any recorded usage history. |
| Prolonged Use (≥ 5 Years) | 1 in 17,000 women | Risk increases notably after five years of treatment. |
| Extended Use (7+ Years) | Risk doubled vs. non-users | Relative risk multiplier peaks at seven years; reverses one year post-discontinuation. |
Regulatory Scope, Patient Communications, and Prescriber Guidance
In response to these findings, the ANSM has coordinated an informational campaign.
The European Medicines Agency (EMA), prompted by the French agency for medicines, mandated that this meningioma risk profile be formally incorporated into the product information leaflets of these desogestrel contraceptives. Public health bodies emphasize that while the concern is genuine, the risk profile is significantly lower than that observed with progestins like Androcur, Lutényl, Lutéran, Colprone, or Depo Provera, for which systematic cerebral imaging is recommended.
Contraindications & When to Consult a Doctor
The notification letters instruct women to consult a healthcare professional immediately if they experience persistent headaches, visual disturbances, muscle weakness, balance or speech disorders, memory loss, or new-onset or worsening epilepsy.
When these symptoms manifest, physicians may order structural neuroimaging, such as a brain MRI, to rule out the formation of a meningioma. Regulators emphasize that individuals should not discontinue their birth control independently. Abrupt cessation without alternative birth control methods creates a risk of unintended pregnancy.
References
- Agence nationale de sécurité du médicament et des produits de santé (ANSM). Official communications and patient notification directives regarding desogestrel-only contraceptives.
- Epi-Phare. Scientific reports on progestogens and the associated risk of intracranial meningioma in France, 2024.
- European Medicines Agency (EMA). Regulatory updates concerning product information modifications for desogestrel 75 microgram formulations.
